Related Experiment Videos
[Anthracycline cardiotoxicity evaluated by digitized M-mode echocardiography]
T Sakamaki1, T Uchiyama, Y Fujibayashi
1Department of Cardiology, Surugadai Nihon University Hospital, Tokyo.
Journal of Cardiology
|January 1, 1992
Summary
Anthracycline chemotherapy can impair left ventricular diastolic function, indicated by reduced thinning rates, while systolic function remains stable. These diastolic changes are temporary, recovering within one month post-treatment.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Context:
- Anthracycline derivatives are widely used chemotherapy agents.
- Cardiotoxicity is a significant concern with anthracycline therapy.
- Early detection of cardiac dysfunction is crucial for patient management.
Purpose:
- To evaluate the impact of anthracycline therapy on left ventricular systolic and diastolic functions.
- To compare the sensitivity of diastolic versus systolic indices in detecting early cardiac impairment.
Summary:
- Computer-assisted echocardiography assessed cardiac function in 10 patients receiving anthracyclines.
- Left ventricular diastolic function indices, including peak LV dD/dt and wall thinning rates, showed significant decreases one week after treatment.
- Systolic function, measured by fractional shortening (%FS), remained unchanged, and diastolic function recovered within one month.
Impact:
- Diastolic function indices are more sensitive than systolic indices for detecting early cardiac impairment during anthracycline therapy.
- Findings suggest regular monitoring of diastolic function may be beneficial for patients undergoing anthracycline treatment.
- This research aids in understanding and mitigating anthracycline-induced cardiotoxicity.